1 citations
,
August 2024 in “British Journal of Dermatology” This study found that after 15 months of treatment with ritlecitinib, patients with alopecia areata and less than 95% initial hair loss experienced significant hair regrowth, though those with more extensive hair loss showed more variable improvement.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” In this study, patients with alopecia areata who didn't initially respond to ritlecitinib at Week 24 showed improved response rates by Week 48, with up to 34% achieving better hair regrowth outcomes.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.
September 2026 in “JID Innovations” This study found that in alopecia areata patients, starting ritlecitinib treatment within one year of an episode led to better hair regrowth outcomes compared to starting after a year.
November 2023 in “SKIN The Journal of Cutaneous Medicine” This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.